文献速递临床试验与 GCP流行病学与生物统计

COVID-19恢复期血浆治疗:随机对照试验前瞻性meta分析方案

Convalescent plasma therapy for COVID-19 patients: a protocol of a prospective meta-analysis of randomized controlled trials.
PubMed 文献 · Trials · 2021-02-01

本方案拟开展前瞻性meta分析,评估恢复期血浆治疗COVID-19对死亡率、多器官衰竭、ICU停留时间和不良事件的影响。将系统检索五个试验注册库及四个数据库,纳入已注册的随机对照试验,由两名作者独立筛选与提取数据,按Cochrane协作网推荐进行数据合成。

要点

  • 前瞻性meta分析聚焦死亡、多器官衰竭、ICU停留及不良事件。
  • 系统检索试验注册库与数据库,纳入已注册随机对照试验。
  • 二分类结局计算合并风险比及95%CI,P<0.05为显著。

核心结论

  • 恢复期血浆是COVID-19值得研究的治疗选择,本前瞻性meta分析旨在评估其疗效与安全性。

研究设计与样本

  • 前瞻性meta分析,系统检索五个试验注册库中已注册的随机对照试验。
  • 将按月持续检索MEDLINE、Embase、CENTRAL和Web of Science以获取已注册RCT的结果。
  • 由两名作者独立筛选,另两名独立评审者提取数据,分歧由第三名研究者解决。

关键数值与推荐

  • 二分类结局(死亡和器官衰竭)从2×2表计算合并风险比及95%CI。
  • 优先采用多变量调整模型数据(风险比、比值比、风险比)。
  • P<0.05视为有统计学显著性。
  • ICU停留计算加权均数差及95%CI。
  • 用I2和χ2检验异质性;至少3项研究报告同一结局和人群时进行meta分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Coronavirus disease 2019 (COVID-19) is an infection with possible serious consequences. The plasma of recovered patients might serve as treatment, which we aim to assess in the form of a prospective meta-analysis focusing on mortality, multi-organ failure, duration of intensive care unit stay, and adverse events. METHODS: A systematic search was conducted to find relevant registered randomized controlled trials in five trial registries. A comprehensive search will be done continuously on a monthly basis in MEDLINE (via PubMed), Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science to find the results of previously registered randomized controlled trials. The selection will be done by two independent authors. Data extraction will be carried out by two other independent reviewers. Disagreements will be resolved by a third investigator. An update of the search of the registries and the first search of the databases will be done on the 21st of July. Data synthesis will be performed following the recommendations of the Cochrane Collaboration. In the case of dichotomous outcomes (mortality and organ failure), we will calculate pooled risk ratios with a 95% confidence interval (CI) from two-by-two tables (treatment Y/N, outcome Y/N). Data from models with multivariate adjustment (hazard ratios, odds ratio, risk ratio) will be preferred for the analysis. P less than 0.05 will be considered statistically significant. In the case of ICU stay, weighted mean difference with a 95% confidence interval will be calculated. Heterogeneity will be tested with I2, and χ2 tests. Meta-analysis will be performed if at least 3 studies report on the same outcome and population. DISCUSSION: Convalescent plasma therapy is a considerable alternative in COVID-19, which we aim to investigate in a prospective meta-analysis.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Szakó L, Farkas N, Kiss S, et al. Convalescent plasma therapy for COVID-19 patients: a protocol of a prospective meta-analysis of randomized controlled trials. Trials. 2021. PMID: 33522939. doi:10.1186/s13063-021-05066-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。